Interaction between everolimus and tacrolimus in renal transplant recipients: A pharmacokinetic controlled trial

Transplantation

Volumn 89, Issue 8, 2010, Pages 994-1000

  Pascual, Julio ^a   Del Castillo, Domingo ^b   Cabello, Mercedes ^c   Pallardó, Luis ^d   Grinyó, Josep M ^e   Fernández, Ana M ^f   Brunet, Mercè ^g  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Everolimus; Pharmacokinetics; Renal transplant; Tacrolimus

Indexed keywords

EVEROLIMUS; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOUND HEALING;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; SPAIN; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951296433     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ccd7f2     Document Type: Article

References (28)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
3. Paul LC, Sijpkens WJ, De Fijter JW. Calcineurin inhibitors and chronic renal allograft dysfunction: Not enough or too much? Transplant Rev 2001; 15: 82.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor neph-rotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
6. Vu MD, Qi S, Xu D, et al. Tacrolimus (TAC506) and sirolimus (rapa-mycin)in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
7. Hariharan S, Tomlanovich S, Filo R, et al. Pharmacokinetics and toler-ability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients [abstract]. J Am Soc Nephrol 2001; 12: 893.
8. Srinivas TR, Meier-Kriesche H-U, Kaplan B.Everolimus in renal transplantation. Curr Opin Organ Transpl 2002; 7: 259.
9. Nielsen FT, Ottosen P, Starklint H, et al. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacroli-mus and sirolimus in the rat. Nephrol Dial Transplant 2003; 18: 491.
10. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy: Report of the European Consensus Conference. Ther Drug Monit 2009; 31: 139.
11. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: Application of a classification system for a clinical decision making. Biopharm Drug Dispos 2006; 27: 421.
12. Masuda S, Uemoto S, Goto M, et al. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 2004; 75: 352.
13. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451.
14. Schubert M, Venkataramanan R, Holt DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004; 4: 767.
15. Filler G, Womiloju T, Feber J, et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005; 5: 2005.
16. McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacoki-netic study of tacrolimus and sirolimus combination immunosuppres-sion comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346.
17. Baldan N, Rigotti P, Furian L, et al. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients. Pharmacol Res 2006; 54: 181.
18. Gonwa T, Mendez R, Yang HC, et al; Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 1213.
19. Guillen D, Millan O, Rimola A, et al. Specific methods for simultaneous determination of calcineurin and mTOR inhibitor immunosuppressants in human whole blood by LC/MS/MS. Anal Bioanal Chem (in press).
20. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
21. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria\An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
22. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of TAC and cyclosporine on EVL. Transplant Proc 2006; 38: 3456.
23. Vanrenterghem Y, van Hooff JP, Squifflet JP, et al; European Tacroli-mus/MMF Renal Transplantation Study Group. Minimization of im-munosuppressive therapy after renal transplantation: Results of a randomized controlled trial. Am J Transplant 2005; 5: 87.
24. Pascual J. Concentration-controlled everolimus (Certican): Combination with reduced-dose calcineurin inhibitors. Transplantation 2005; 79: S76.
25. Chan L, Greenstein S, Hardy MA, et al; CRADUS09 Study Group. Multicenter, randomized study of the use of everolimus with tacroli-mus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
26. Kahan BD, Kaplan BD, Lorber MI, et al. RAD in the novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400.
27. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861.
28. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: A review of clinical trial data, current usage and future directions. Transplant Rev 2006; 20: 1.